Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00428545 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab and Bortezomib in Patients With Advanced Malignancy
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT00428545: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00428545 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 104 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00428545, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Avastin™ (bevacizumab) and Velcade™ (bortezomib) that can be given in combination to patients with a metastatic or unresectable advanced malignancy. The safety and effectiveness of this drug combination will also be studied.
Interventions
- DRUG Bevacizumab
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2007-01 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00428545
The ClinicalTrials.gov registry entry for NCT00428545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT00428545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00428545 about?
NCT00428545 is a clinical study titled "Bevacizumab and Bortezomib in Patients With Advanced Malignancy". The goal of this clinical research study is to find the highest tolerable dose of Avastin™ (bevacizumab) and Velcade™ (bortezomib) that can be given in combination to patients with a metastatic or unresectable advanced malignancy. The safety and effectiveness of this drug combination will also be st...
What is the current status of trial NCT00428545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2007-01. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00428545?
The interventions under investigation include: Bevacizumab (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00428545?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.